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Abstract
Background: Granulomatosis with polyangiitis (GPA, formerly Wegener’s granulomatosis) is a multisystem vasculitis of
small- to medium-sized blood vessels. Cranial involvement can result in cranial nerve palsies and, rarely, pituitary infiltration.
Case presentation:We describe the case of a 32 year-old woman with limited but severe GPA manifesting as
progressive cranial nerve palsies and pituitary dysfunction. Our patient initially presented with localised ENT involvement,
but despite treatment with methotrexate, she deteriorated. Granulomatous inflammatory tissue around the skull base
resulted in cavernous sinus syndrome, facial nerve palsy, palsies of cranial nerves IX-XII (Collet-Sicard syndrome), and the
rare complication of cranial diabetes insipidus due to pituitary infiltration. The glossopharyngeal, vagus and accessory
nerve palsies resulted in severe dysphagia and she required nasogastric tube feeding. Her neurological deficits
substantially improved with treatment including high dose corticosteroid, cyclophosphamide and rituximab.
Conclusions: This case emphasises that serious morbidity can arise from localised cranial Wegener’s granulomatosis in
the absence of systemic disease. In such cases intensive induction immunosuppression is required. Analysis of previously
reported cases of pituitary involvement in GPA reveals that this rare complication predominantly affects female patients.
Keywords: Granulomatosis with polyangiitis, Wegener’s granulomatosis, Vasculitis, Diabetes insipidus, Pituitary, Collet-
Sicard syndrome, Cavernous sinus syndrome, ANCA, Rituximab, Cyclophosphamide
Background
Granulomatosis with polyangiitis (GPA, formerly Wege-
ner’s granulomatosis) is an autoimmune vasculitis of
small- to medium-sized blood vessels. The Chapel Hill
2012 Consensus Criteria define GPA as “necrotizing
granulomatous inflammation usually involving the upper
and lower respiratory tract and necrotizing vasculitis
affecting predominantly small to medium vessels” [1]. In
their seminal 1954 review, Godman and Churg recognized
that Wegener’s granulomatosis, microscopic polyangiitis,
and Churg-Strauss syndrome shared certain clinico-
pathological features, and comprised a subset of vasculit-
ides distinct from ‘periarteritis nodosa’ (now polyarteritis
nodosa) [2]. The discovery that anti-neutrophil cytoplas-
mic antibodies (ANCA) are present in over 90% of
patients with GPA and microscopic polyangiitis, and
approximately 30% of those with Churg-Strauss syndrome
has led to these three clinical syndromes being classified
under the umbrella term ‘ANCA-associated vasculitis’. Pa-
tients with GPA typically show a cytoplasmic pattern of
ANCA staining on indirect immunofluorescence (‘cANCA
pattern’), with antibodies directed against proteinase-3
(PR3), a neutrophil protease.
The generalised form of GPA described by Wegener is
characterized histopathologically by the triad of necrotizing
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vasculitis, pauci-immune focal necrotizing glomeruloneph-
ritis and necrotizing granulomatous inflammation of the
respiratory tract. This systemic form of the disease can
be life-threatening, particularly in the presence of pul-
monary haemorrhage or rapidly progressive crescen-
teric glomerulonephritis. Prior to the introduction of
cyclophosphamide [3], mortality was over 80% [4].
Modern treatment involves intensive immunosuppres-
sive therapy with high dose corticosteroids and cyclo-
phosphamide or rituximab to induce remission [5, 6].
Once remission is achieved, patients are switched to
less toxic maintenance immunosuppression, such as
azathioprine and low dose glucocorticosteroid.
A limited form of Wegener’s granulomatosis, with le-
sions localised to the lung, was later identified [7]. Patients
with limited (now generally referred to as ‘localised’) dis-
ease are more likely to be young, female and ANCA nega-
tive than those with generalised GPA [8]. Localised GPA
typically manifests with middle ear and respiratory tract
features such as otitis media, sinusitis, nasal collapse and
airway stenosis [8, 9].
Here we describe a patient with localised but severe
granulomatosis with polyangiitis (Wegener’s granulomato-
sis) manifesting with progressive cranial nerve palsies and
pituitary dysfunction. This case emphasises that localised
cranial Wegener’s granulomatosis can result in serious
morbidity in the absence of systemic disease. In such cases
intensive induction immunosuppression is required.
Case presentation
Our patient, a white British female, presented at the age
of 32 years with epistaxis, nasal congestion, recurrent bi-
lateral otitis media and progressive hearing loss to an
Ear, Nose and Throat (ENT) clinic at her local hospital.
A year prior to this she had been fitted with bilateral
hearing aids for hearing loss of unknown cause. She sub-
sequently developed a left lower motor neurone facial
palsy. A computed tomography (CT) scan showed a left
nasopharyngeal mass and inflammatory changes in the
middle ear and mastoid air cells. Nasolaryngoscopy re-
vealed inflammation and ulceration of the left nasal tur-
binate, septum and posterior pharyngeal wall. She had
never used cocaine. She underwent an exploratory mas-
toidectomy with grommet insertion.
Biopsies of the right and left nasopharynx, left middle
meatus and septum revealed florid acute and chronic
inflammation with mucosal ulceration and extensive ne-
crosis of stroma and cartilage. The inflammatory infil-
trate consisted of neutrophils, lymphocytes, and plasma
cells, with zones of histiocytes representing granulomata
(Fig. 1). Large numbers of multinucleated giant cells
were present. Eosinophils were inconspicuous. Histo-
logical assessment of vasculitis was difficult due to the
extensive necrosis and marked tissue inflammation, but
necrotizing vasculitis of small vessels was evident. There
was no evidence of malignancy, and stains for fungi and
mycobacteria were negative.
Anti-neutrophil cytoplasmic antibody (ANCA) testing
was positive by immunofluorescence with a cytoplasmic
staining pattern. Anti-proteinase-3 (PR3) antibodies
measured by enzyme-linked immunosorbent assay
(ELISA) were mildly elevated (5.8, normal range < 2).
Anti-myeloperoxidase (MPO) antibodies were not
detected. CT thorax revealed no pulmonary abnormal-
ity and no lymphadenopathy. Serum calcium and
angiotensin-converting enzyme (ACE) were normal.
On the basis of the clinico-pathological findings, she
was diagnosed with localised granulomatosis with poly-
angiitis (GPA, formerly known as Wegener’s granulo-
matosis). Detailed work-up revealed no evidence of
pulmonary, renal or other systemic features. She was
treated with methotrexate 25 mg weekly and prednisol-
one 60 mg daily. The prednisolone was weaned to
10 mg over a period of 6 months. As the steroid dose
was reduced she deteriorated. She developed head-
aches, nausea, diplopia, dysphonia and progressive dys-
phagia to both solids and liquids, resulting in weight
loss of 3 stone.
She was referred to our institution by her general
practitioner approximately 1 year after her initial
presentation. Physical examination revealed left ptosis, a
dilated and unreactive left pupil, paresis of left eye
movements consistent with palsies of cranial nerves III,
IV and VI, a left lower motor neurone facial palsy, and
deviation of the tongue to the right. There was wasting
of the right sternocleidomastoid. Laryngoscopy revealed
a right-sided vocal cord palsy. Blood tests showed mild
elevation of the inflammatory markers; the erythrocyte
sedimentation rate (ESR) was 34 mm/hour, and the
C-reactive protein (CRP) was 26 mg/L. Renal function,
urinalysis and urine microscopy were normal. Repeat
ANCA testing revealed cytoplasmic pattern ANCA
staining, but antibodies to PR3 and MPO were negative.
Fig. 1 Histopathology. Nasal biopsy. H&E stain, magnification X100.
Vertical arrows show granuloma. Horizontal left facing arrow: necrosis.
Horizontal right facing arrow: angiitis with necrosis in vessel wall.
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A contrast-enhanced CT scan of her head and neck
(Fig. 2) demonstrated predominantly dural-based enhan-
cing soft tissue abnormality affecting the central skull
base. This chronic inflammatory tissue involved the sella
turcica (with resultant erosion of the floor of the sella tur-
cica) and both cavernous sinuses. There was associated
abnormality involving the pituitary parenchyma, the pitu-
itary stalk and the hypothalamus. Contiguous chronic in-
flammatory infiltrative changes were also evident in the
orbital apices, the petrous temporal bones encasing the
carotid canals and the extra-cranial infratemporal fossae
including the pterygopalatine fossae. As a result of the
cavernous sinus, petrous temporal bone and infratemporal
fossae involvement, both internal carotid arteries were oc-
cluded in their skull base carotid canal segments, with the
anterior circulation sustained through collateral vessels. The
sinonasal region demonstrated chronic inflammatory fea-
tures, with mucosal and submucosal fibrosis and ulceration.
Bilateral chronic middle ear and mastoid inflammatory
changes were evident. Radiological features of right Collet-
Sicard syndrome (palsy of cranial nerves IX-XII) were also
present. The appearances, particularly in relation to the
skull base infiltration, had progressed significantly com-
pared to 6 months earlier. Her pituitary hormone profile
showed elevated prolactin (1353 munit/L; upper limit of
normal range = 496) and reduced thyroid-stimulating hor-
mone (TSH) (0.23 munit/L) with normal free thyroxine. On
further enquiry, she reported amenorrhoea for the past year.
She had not yet had any children and was keen to do
this in the future. We therefore initially opted for treat-
ment with rituximab over cyclophosphamide. She received
Rituximab 1 g, with a plan for a second dose two weeks
later. Methotrexate was replaced with Azathioprine. She
Fig. 2 Coronal contrast-enhanced CT image of the skull base and
neck (pre-cyclophosphamide treatment). There is marked abnormal
chronic inflammatory infiltration of the cavernous sinuses bilaterally (bold
white arrow) and hypophyseal involvement (black arrow). Multiple lower
cranial nerve palsies (Collet-Sicard syndrome) as a result of the skull base
inflammatory involvement were evident on imaging, including right
vocal cord palsy indicated by adducted right true vocal cord and
enlarged right laryngeal ventricle (long white arrow)
Fig. 3 Coronal T2-weighted MRI image of the skull base and neck
(pre-cyclophosphamide treatment). There is severe chronic
inflammatory soft tissue abnormality affecting the cavernous sinuses
and central and lateral skull base, including the left cavernous sinus
and right sphenoid bone and foramen rotundum (large black arrows).
Secondary cranial nerve palsies are present. Palsy of the mandibular
division of the right trigeminal nerve has resulted in atrophy of the
right masticator space muscle, in comparison to the more normal
muscle volume on the left (short white arrows). Lower cranial nerve
palsies are demonstrated by atrophy of the right superior pharyngeal
constrictor muscle (short black arrow) and sternocleidomastoid
muscles (long white arrows)
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also received one pulse of intravenous (i.v.) methyl pred-
nisolone 500 mg, and her oral prednisolone was increased
from 10 mg to 30 mg. Given her modest baseline im-
munosuppressive treatment, and because of the insidious
presentation and lack of systemic features, at the time we
felt this mid-range prednisolone dose rather than 1 mg/kg
was reasonable. Her CRP fell to 6 mg/L and she was dis-
charged from hospital.
She was seen as an emergency 10 days later. She had
developed complete dysphagia to solids and liquids and
was unable to manage even small sips of water. Both pu-
pils were now dilated and reacted sluggishly to light, and
she had a new right-sided ptosis, indicating a new right-
sided third nerve palsy. She also had a new right-sided
sixth nerve palsy. Assessment of her swallowing showed
that she was aspirating and had an ineffective cough re-
flex. She was kept nil-by-mouth, and fed through a naso-
gastric tube. The safety of her airway was assessed by
the anaesthetic and ENT teams because of concern that
she was at high risk of life-threatening airway obstruc-
tion or aspiration should the vocal cord palsies become
bilateral. Her CRP had risen to 33 mg/L.
A cranial magnetic resonance imaging (MRI) scan
(Figs. 3 and 4a) confirmed the CT findings, and provided
greater imaging sensitivity and specificity regarding the
extent and severity of the osseus skull base infiltrative
changes, the intracranial dural-based disease burden,
and the cranial nerve palsies. Muscle atrophy due to de-
nervation as a result of the latter was particularly well
demonstrated. In addition, the MRI provided greater de-
tail on the degree of hypothalamic-pituitary axis involve-
ment, and allowed for subsequent imaging assessment of
response to treatment.
She was treated with three pulses of i.v. methyl prednis-
olone 500 mg, with rapid improvement in her diplopia
and normalization of the CRP. The right pupillary abnor-
mality improved but the left pupil remained dilated (Fig.
5). Her oral prednisolone was increased to 60 mg, and she
received three fortnightly doses of i.v. cyclophosphamide
750 mg (15 mg/kg) followed by three further doses at
three-weekly intervals. Azathioprine was stopped. She also
was given the second rituximab dose. She received topical
mupirocin to reduce nasal Staphylococcus carriage and
was started on oral co-trimoxazole both to reduce the risk
of opportunistic infections and because this may reduce
relapses in GPA [10]. Her swallowing remained compro-
mised and she remained an inpatient for ongoing feeding
via the nasogastric tube. Subsequently a percutaneous gas-
trostomy tube was inserted.
Her admission was complicated by hypernatraemia
with serum sodium rising to 157 mmol/L. She required
4–5 L of fluid per day to maintain her sodium level in
the normal range. She had two episodes of syncope due
to postural hypotension. Her fluid balance chart revealed
polyuria. Blood glucose and calcium were normal. Re-
peat dedicated pituitary MRI showed pathological en-
hancement and diffuse thickening of the pituitary (Fig. 4
b&c). She was diagnosed with cranial diabetes insipidus
and treated with desmopressin, with normalization of
her serum sodium. She was discharged home with feed-
ing via the gastrostomy tube.
After six pulses of cyclophosphamide, she showed
marked clinical improvement. Her diplopia had resolved
and eye movements had returned to normal. She was
able to eat and drink normally. Her right-sided third
nerve palsy had entirely resolved. Her left pupil
remained dilated and reacted sluggishly to light, and a
mild left facial weakness persisted. A further cranial MRI
showed marked regression of the inflammatory changes
in the skull base (Fig. 6). She was switched to mainten-
ance therapy with azathioprine, and the prednisolone
dose was slowly weaned to 5 mg daily. She remained
clinically well on this treatment, with no progression of
cranial disease on MRI, for 20 months following comple-
tion of cyclophosphamide. At this point, she had a re-
lapse of ENT disease with nasal blockage and epistaxis
requiring a tapering course of prednisolone 30 mg daily.
Discussion
Our patient first presented with localised GPA confined
to the nasopharynx and ear. Despite initial treatment
with full-dose methotrexate and steroids, her disease
progressed. She developed the unusual complications of
extensive cranial nerve palsies (involvement of nerves II-
IV, V3, and VI-XII) and diabetes insipidus due to granu-
lomatous infiltration of the skull base.
Our report highlights several learning points. First, it
demonstrates that localised GPA can be aggressive and
result in serious morbidity. Assessment of disease sever-
ity is a key aspect of the management of AAV since it
guides treatment decisions [5, 6]. Disease severity can be
classified as life-threatening, organ-threatening (i.e. dis-
ease that will result in permanent tissue damage and/or
loss of function unless appropriately treated), or non-
organ threatening. Although our patient had anatomic-
ally localised cranial GPA, she developed organ-
threatening disease with severe progressive cranial nerve
involvement as a result of compression by inflammatory
tissue. This included a vocal cord palsy, which resulted
in dysphonia. If she had not been treated promptly, this
could have become bilateral which can lead to life-
threatening airway obstruction [11]. Glossopharyngeal,
vagus and accessory nerve palsies resulted in severe dys-
phagia necessitating nasogastric feeding.
Second, this case illustrates central nervous system
(CNS) manifestations of GPA, including the rare compli-
cation of cranial diabetes insipidus due to pituitary infil-
tration and compression. In contrast to peripheral nerve
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involvement, CNS disease in GPA is uncommon. In a
European cohort of 128 GPA patients, 56 patients (44%)
had peripheral neuropathy (either symmetrical polyneur-
opathy or mononeuritis multiplex), whilst only 9 pa-
tients (7%) had CNS involvement, of whom 6 had
cranial nerve palsies [12]. CNS involvement occurred in
8% of cases in a cohort from the National Institutes of
Health (NIH) [13], and cranial nerve palsies occurred in
21 of 324 patients (6%) attending the Mayo Clinic [14].
CNS disease in GPA is proposed to develop by three dis-
tinct but sometimes co-existing mechanisms [15]: by
contiguous spread of granulomatous tissue from adja-
cent sites in the middle ear and sinuses (as in our pa-
tient), by primary granuloma formation within the CNS,
or from vasculitis affecting the CNS. Seror et al. de-
scribed three patterns of GPA-related CNS disease:
chronic hypertrophic pachymeningitis, pituitary gland
involvement, and cerebral vasculitis [16].
Yokoseki et al. reported a series of 36 patients with
hypertrophic pachymengitis, of whom 17 had ANCA
against MPO and 4 against PR3 [17]. Although the num-
ber of PR3 positive patients was small, this study found a
higher frequency of pulmonary and renal disease in PR3
positive cases than in MPO+ cases, and that leptomenin-
geal and parenchymal involvement in the brain were more
common in PR3 positive hypertrophic pachymeningitis
compared with MPO positive and idiopathic hypertrophic
pachymeningitis. In the presence of leptomengingeal AAV,
Fig. 4 MR images of the brainstem, skull base and pituitary gland.
(a) Coronal contrast-enhanced fat-saturated T1-weighted image of
the central skull base demonstrates pathological enhancement of
the cavernous sinus, pituitary gland and pituitary stalk (arrow). The
abnormalities are non-discrete and radiologically inconsistent with a
microadenoma or invasive macro adenoma of the pituitary gland.
(b) Dedicated thin-section coronal contrast-enhanced T1-weighted
image of the pituitary demonstrates the abnormal enhancement
and thickening of the pituitary stalk as well as the cavernous sinus
and pituitary parenchyma in more detail. (c) Dedicated thin-section
sagittal contrast-enhanced T1-weighted image of the pituitary
demonstrates the abnormal generalised thickening and
enhancement of the pituitary stalk (arrow) consistent with
granulomatous infundibulitis
Fig. 5 Photograph demonstrating dilated left pupil and nasal
deformity. This was taken after 3 pulses of i.v. methyl prednisolone
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cerebrospinal fluid analysis may reveal elevated protein
and pleiocytosis, but these findings are non-specific. Other
causes of hypertrophic pachymeningitis include other
immune-mediated diseases (e.g. sarcoidosis and IgG4-
related disease), infections, and neoplasms (particularly
lymphoma) [17]. Lymphoma mimicking GPA with posi-
tive PR3 antibodies has been described [18]. However, in
our patient, the radiological picture and the clinical course
were not consistent with lymphoma.
Our patient had both chronic pachymeningitis and pi-
tuitary gland involvement, with meningeal thickening
and pituitary infiltration evident on cranial imaging, and
clinical and biochemical evidence of pituitary disease. Pi-
tuitary dysfunction due to GPA is rare, occurring in 9 of
819 patients (1.1%) in the French Vasculitis Study Group
database [19], and 8 of 637 patients (1.3%) in a series
from the Mayo Clinic [20]. We identified 58 previously
reported cases of GPA with sellar involvement in the litera-
ture (Table 1), and analysed their clinical and demographic
features. There was a significant female preponderance; 40
(69%) of the patients were female. Patients with pituitary in-
volvement tended to be younger than GPA patients in gen-
eral (median age at time of pituitary involvement 39.
5 years, interquartile range 29–50 years). Pituitary involve-
ment generally occurred early in the disease course. Of 46
cases where we were able to identify the age of onset of
both GPA and pituitary involvement, in 28 (61%), pituitary
disease was either the presenting feature or was diagnosed
within a year of GPA onset. ENT involvement was the most
common additional clinical GPA manifestation, occurring
in 39 patients (67%). Other extra-CNS manifestations were,
in order of decreasing frequency, pulmonary (n = 25), renal
(n = 16), musculoskeletal (n = 15), ocular (n = 14), mucocu-
taneous (n = 12), peripheral neuropathy (n = 4), cardiac (n
= 1), digital infarcts (n = 1), gastro-intestinal (n = 1). Dia-
betes insipidus was the most common endocrine abnormal-
ity, occurring in 47 patients (81%). In 4 of these, diabetes
insipidus occurred following sellar surgery. Anterior pituit-
ary hormone abnormalities occurred less frequently: hypo-
gonadism was present in 32 patients, secondary
hypothyroidism in 20, hyperprolactinaemia in 19, and
growth hormone deficiency in 5. Reliable estimation of the
frequency of adrenocorticotropic hormone (ACTH) defi-
ciency was difficult due to therapeutic administration of ex-
ogenous corticosteroids in many cases. Typical MRI
appearances include a sellar mass, sometimes with supra-
sellar extension, diffuse enlargement of the pituitary, thick-
ening of the infundibulum (pituitary stalk), and
enhancement with gadolinium contrast. Loss of the normal
posterior pituitary hyperintensity on T1 weighted images
was reported in 17 cases, and correlated with the presence
of diabetes insipidus. In a few cases, hyperprolactinaemia
and the presence of a pituitary lesion on imaging caused
diagnostic confusion with a prolactinoma [21, 22]. How-
ever, diabetes insipidus and the loss of the normal high sig-
nal in the posterior pituitary on T1 weighted MRI are
unusual in small pituitary adenomas. Our patient had dif-
fuse pituitary and infundibular changes radiologically in-
consistent with a pituitary adenoma.
The third issue raised by this case is the wisdom of
methotrexate treatment at the time of her initial presen-
tation. The NORAM trial compared methotrexate with
cyclophosphamide for the treatment of early, non-organ
threatening systemic disease [23]. Whilst there was no
significant difference in the primary endpoint of overall
remission rates at 6 months, relapse rate at 18 months
was higher in the methotrexate group, and there was
delayed remission in the methotrexate group in patients
with more extensive disease or pulmonary involvement.
The lack of a difference between methotrexate and
cyclophosphamide at 6 months might reflect the fact
that patients in both treatment groups were still receiv-
ing steroids at this timepoint. Post-trial follow-up has
revealed that patients in the methotrexate arm of the
trial received more corticosteroids, cyclophosphamide,
and other immunosuppressive agents than those in the
cyclophosphamide group [24], indicating less effective
disease control with methotrexate compared to cyclo-
phosphamide induction therapy. In light of these data and
our clinical experience, it is the authors’ personal view that
methotrexate should be used for only the mildest cases of
GPA, and we have a low threshold for switching to stron-
ger immunosuppressive therapy in the face of active
Fig. 6 Axial intracranial contrast-enhanced T1-weighted MR
image after six pulses of cyclophosphamide. There is reduction
in the volume of abnormal cavernous sinus enhancing chronic
inflammatory tissue (arrows) compared with pre-treatment imaging
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Table 1 Previous reports of sellar involvement in GPA
1st Author
& year
PMID No.
of cases
Age at GPA
diagnosis
Age at time
of sellar involvement
Sex Pituitary Imaging
(MRI unless stated)
Endocrinological
abnormalities
Non-CNS
features
ANCA
Haynes
1978 [29]
692550 1 26* 25 M NA DI Hyperprolactinaemia
Normal TSH
Normal LH & FSH
Lung, renal N/A
Hurst 1983
[30]
6625709 1 47* 47 F CT normal DI Normal prolactin
Normal TSH
Post-menopausal
LH/FSH
Polyarthritis, ENT,
ocular,
mucocutaneous,
pulmonary
N/A
Lohr 1988
[31]
3172100 1 19* 19 F Intrasellar mass N/A ENT, pulmonary N/A
Rosete 1991
[32]
1865428 1 51* 51 F CT: pituitary
enlargement
DI N/A N/A
Czarnecki
1995 [33]
7611087 1 31 34 F Sellar mass with
suprasellar extension.
Enhancement of the
stalk and
hypothalamus.
Loss of PS.
DI
Hyperprolactinaemia
ENT, arthralgia N/A
Roberts
1995 [34]
7758239 2 71* 71 F Intrasellar mass with
suprasellar extension
DI (post-surgery)
↓ TSH
↓ LH & FSH
↓ cortisol
Normal prolactin
None cANCA +ve
28* 28 F Intrasellar mass with
low-density centre
DI (post-surgery)
Normal prolactin
Normal TSH
Normal LH & FSH
Normal cortisol
Ocular,
arthralgia,
cutaneous, renal
cANCA +ve
Bertken
1997 [35]
9265867 1 36* 36 F Macrocystic pituitary
mass with
suprasellar extension.
Hydrocephalus
DI (post surgery) ↓
TSH response ↓ LH &
FSH responses
ENT, pulmonary,
ocular
ANCA -ve
Hajj-Ali 1999
[36]
10461488 1 N/A 21 F Normal DI N/A N/A
Katzman
1999 [21]
10219422 2 41* 41 F Pituitary
enlargement. Loss
of PS
DI
Hyperprolactinaemia
Normal TSH Normal
LH & FSH
Constitutional,
arthralgia, ENT,
ocular,
cutaneous
cANCA +ve
18* 18 F Pituitary
enlargement with
contrast-
enhancement.
Loss of PS
DI
Hyperprolactinaemia
Normal TSH
Normal LH & FSH
ENT, pulmonary cANCA +ve
Miesen 1999
[37]
10069203 1 46* 45 M Stalk thickening,
contrast-
enhancement.
Loss of PS
DI
Hyperprolactinaemia
Hypogonadism
Normal TSH
Normal LH & FSH
Normal cortisol &
ACTH
ENT, renal,
pulmonary
ANCA +ve
Goyal 2000
[38]
11003280 1 N/A (many
years before
pituitary
involvement)
48 F Sellar mass with
suprasellar extension.
Contrast-
enhancement
DI
↓ TSH
Renal,
pulmonary
cANCA +ve
Tappouni
2000 [39]
11096156 1 58* 57 F Pituitary mass DI Constitutional,
ENT, cutaneous,
renal, pulmonary
PR3 +ve
Woywodt
2000 [40]
11028850 1 30* 30 M N/A (diagnosed
at autopsy)
N/A N/A N/A
Garovic
2001 [41]
11136194 1 47* 47 F Cystic enlargement
of the pituitary.
Non-enhancing with
gadolinium
DI
↓ prolactin
↓ TSH
↓ gonadotropins
Constitutional,
cutaneous,
pulmonary
cANCA +ve
Tao 2003
[42]
14642162 1 N/A 19 F Pituitary and stalk
enlargement with
heterogenous
enhancement
DI
↓ TSH
Hypogonadism
N/A N/A
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Table 1 Previous reports of sellar involvement in GPA (Continued)
1st Author
& year
PMID No.
of cases
Age at GPA
diagnosis
Age at time
of sellar involvement
Sex Pituitary Imaging
(MRI unless stated)
Endocrinological
abnormalities
Non-CNS
features
ANCA
Muir 2004
[43]
15150009 1 13* 13 M Diffuse pituitary
enlargement.
Foci of ↑ T1 signal.
More extensive ↑ T2
signal. Central
contrast-
enhancement.
Loss of PS.
DI ENT, pulmonary ANCA +ve
Vittaz 2004
[44]
15687906 2 45 47 M Pituitary mass, with
contrast-
enhancement.
Pituitary stalk
thickened &
infiltrated.
Loss of PS
Hyperprolactinaemia
↓ testosterone
↓ LH, normal FSH
↓ cortisol & ACTH
Normal TSH
Constitutional,
polyarthritis,
peripheral
neuropathy,
pulmonary
PR3 +ve
46 50 F Pituitary enlargement DI
Hyperprolactinaemia
Hypogonadism
Polyarthritis,
ocular,
mucocutaneous,
ENT
ANCA +ve
Duzgun
2005 [45]
15864593 1 47* 47 F Loss of PS DI
Anterior pituitary
hormones normal
Polyarthritis,
pulmonary, ENT,
renal
PR3 +ve
Seror 2006
[16]
16523054 3 45 50 F Nodular pituitary
enlargement.
Homogenous
contrast-
enhancement.
Loss of PS
DI
Hyperprolactinaemia
Thyrotropic
deficiency
Hypogonadism
Corticotropic
deficiency
ENT, ocular,
mucocutaneous
PR3 +ve
26 41 F Nodular pituitary
enlargement.
Contrast-
enhancement
DI
Normal anterior
pituitary hormones
ENT, arthralgia,
ocular, renal
PR3 +ve
55 57 M Pituitary
enlargement &
central necrosis.
Heterogenous
enhancement.
DI
Hyperprolactinaemia
Panhypopituitarism
Peripheral
neuropathy,
pulmonary,
retinal vasculitis,
digital, cerebral
and renal
infarcts
PR3 +ve
Spisek 2006
[46]
16322901 1 30* 29 M Sellar cystic lesion DI
↓ TSH
↓ LH & FSH
↓ ACTH
↓ IGF-1
ENT PR3 +ve
McIntyre
2007 [47]
17318440 1 22* 22 F Heterogeneous
enhancing pituitary
mass
DI
Hypogonadism
Cutaneous,
ocular, renal
PR3 +ve
Thiryayi
2007 [48]
17188492 1 21* 21 F Sellar mass with
central hypo-
intensity
DI (post-surgery)
Hypogonadism
(post-surgery)
Constitutional,
arthralgia
cANCA +ve
Yong 2008
[49]
17492510 1 33* 33 M Pituitary stalk
thickening. Contrast-
enhancing nodule at
the superior aspect
of the stalk.
Loss of PS.
DI
Hypogonadism
↓ ACTH
Normal prolactin
Normal TSH
Normal IGF-1
ENT PR3 +ve
Cunnington
2009 [50]
20107566 3 19 24 M Pituitary
enlargement
DI
Anterior pituitary
hormones normal
Constitutional,
ENT, pulmonary,
ocular,
cutaneous
PR3 +ve
33 34 F Diffusely enlarged
gland containing a
poorly enhancing
lesion with supra-
sellar extension. Loss
of PS.
DI
Normal prolactin
Normal TSH
Constitutional,
ENT
cANCA+ve
26 35 M DI
↓ TSH
Constitutional,
ENT, pulmonary
cANCA +ve
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Table 1 Previous reports of sellar involvement in GPA (Continued)
1st Author
& year
PMID No.
of cases
Age at GPA
diagnosis
Age at time
of sellar involvement
Sex Pituitary Imaging
(MRI unless stated)
Endocrinological
abnormalities
Non-CNS
features
ANCA
Diffusely enlarged
pituitary and
thickened stalk.
Xue 2009
[51]
19172275 1 63* 63 F Normal DI
TSH normal
LH & FSH normal
Constitutional,
pulmonary,
peripheral
neuropathy
PR3 +ve
Barlas 2011
[52]
21116602 1 35 37 F Anterior
enlargement.
Central area with
low signal on T1 and
high signal on T2.
Post contrast
enhancement of
pituitary and stalk.
Loss of PS.
DI
Hyperprolactinaemia
ENT, pulmonary,
polyarthritis
cANCA +ve
Santoro
2011 [53]
22147097 1 53* 53 F Hypointensity of
adenohypophysis
on T1.
Hyperintense sectors
on R side on T2.
Peripheral contrast-
enhancement.
Stalk-thickening.
Loss of PS.
DI
↓ TSH
Hypogonadism
Normal prolactin
Polyarthritis,
cutaneous,
pulmonary, renal
cANCA +ve
Tenorio-
Jimenez
2011 [54]
22673710 1 23 38 F MRI: marked
infundibular
thickening, sellar
mass with
hypointensity on T1.
Loss of PS
Hyperprolactinaemia
↓ TSH
Hypogonadism
Post pituitary
hormones
unaffected
ENT, pulmonary,
renal
cANCA +ve
(−ve by the
time of sellar
manifestations)
Hughes
2013 [55]
23186961 1 N/A 30 F Sellar mass Panhypopituitarism Ocular N/A
Pereira 2013
[56]
22898089 1 48* 48 F Appearances of
pituitary
microadenoma, but
histopathlogy
revealed
necrotizing
granulomatous
inflammation
Hyperprolactinaemia
↓ TSH
Post pituitary
hormones
unaffected
ENT N/A
Kapoor 2014
[20]
25077899 8 N/A 67 F Peripherally
enhancing cystic
sellar mass
compressing the
stalk
Hyperprolactinaemia
Hypogonadism
Normal TSH
ENT, renal 7/8 cases
PR3 +ve
N/A 48 F Multiple non-
enhancing cystic
areas in the pituitary,
convexity of superior
margin of pituitary
DI
↓ prolactin
↓ TSH
Hypogonadism
Corticotropic
deficiency
ENT, pulmonary,
cutaneous
N/A 28 F Sellar mass with
large zone of central
non-enhancement
and peripheral
enhancement. Stalk
displacement
DI
Hypogonadism
Normal prolactin
Normal TSH
Normal IGF-1
Normal cortisol
ENT, pulmonary,
renal
N/A 55 M Sellar mass with
suprasellar extension
DI
Hypogonadism
Normal prolactin
Normal TSH
Normal cortisol
Normal IGF-1
ENT, pulmonary,
renal, cutaneous,
joints
N/A 35 M Necrotic sellar mass
with peripheral
enhancement &
suprasellar extension.
Thickened contrast-
enhancing stalk
DI
↓ TSH
Hypogonadism
Normal prolactin
Normal cortisol
Normal IGF-1
ENT
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Table 1 Previous reports of sellar involvement in GPA (Continued)
1st Author
& year
PMID No.
of cases
Age at GPA
diagnosis
Age at time
of sellar involvement
Sex Pituitary Imaging
(MRI unless stated)
Endocrinological
abnormalities
Non-CNS
features
ANCA
N/A 54 M Enlarged pituitary
measuring 12 mm,
with heterogeneous
enhancement. Slight
diffuse thickening of
the stalk
DI
↓ TSH
Hypogonadism
Normal prolactin
Normal IGF-1
ENT, pulmonary,
renal, cardiac
N/A 68 M Homogeneously
enhancing sellar
mass, extending into
the cavernous sinus
bilaterally. Stalk
preserved.
↓ prolactin
↓ TSH
Hypogonadism
↓ IGF-1
ENT, joints
N/A 28 F Sellar mass
extending into the
suprasellar cistern,
with low T2 signal in
the periphery and a
bright centre.
Peripheral
enhancement with
central cystic
change. Thickening
of pituitary stalk
DI
Normal prolactin
Normal TSH
Normal cortisol
Normal IGF-1
ENT
De Parisot
2015 [19]
25906106 9 46* 46 F Enlarged posterior
pituitary. Infiltration
of posterior pituitary.
Loss of PS
DI ENT, ocular
60 70 M Normal ↓ TSH
Hypogonadism
↓ IGF-1
Normal prolactin
ENT, peripheral
neuropathy
23 24 F Enlarged pituitary.
Irregularity of
infundibulum.
Heterogeneous
enhancement of
anterior pituitary.
Loss of PS
DI
↓ TSH
Hypogonadism
Normal prolactin
Normal IGF-1
ENT
24* 24 M Enlarged
infundibulum
DI
Hyperprolactinaemia
↓ TSH
Hypogonadism
Normal IGF-1
Renal, ocular,
joints, gastro-
intestinal
66 77 M Enlarged pituitary.
Stalk infiltration.
Loss of PS.
↓ TSH
Hypogonadism
↓ IGF-1
Normal prolactin
None
67 68 F Normal DI
Hyperprolactinaemia
Normal TSH
Normal LH & FSH
Normal IGF-1
ENT
28 42 F Heterogeneous
enhancement of
pituitary
DI
Hyperprolactinaemia
Hypogonadism
↓ ACTH
ENT, lung
55 57 M Sellar mass,
heterogeneous.
Enhancement. Enlargement and
infiltration of stalk.
Loss of PS
DI
Hyperprolactinaemia
↓ TSH
Hypogonadism
↓ ACTH
Pulmonary
46 50 F Enlargement and
infiltration of
pituitary.
Heterogeneous
enhancement,
contact with optic
chiasm
DI
Hyperprolactinaemia
Hypogonadism
Normal TSH
Normal IGF-1
ENT, ocular
Eli 2016 [22] 27521731 1 32* 29 F Hyperprolactinaemia ENT, pulmonary MPO +ve
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disease. This view is supported by the 2015 EULAR guide-
lines which reserve methotrexate for the treatment of
non-organ threatening disease [6]. The EULAR guidelines
specifically spell out that methotrexate is not suitable ther-
apy for meningeal disease, or for nasal/paranasal disease
with bony involvement, cartilage collapse or deafness, and
thus do not support the use of methotrexate in this pa-
tient, even at the time of her initial presentation. The ab-
sence of pulmonary or renal disease and the perception
that localised disease is benign may have contributed to
her initial under-treatment, and the failure to escalate im-
munosuppression at her local hospital.
The final issue is the choice of rituximab versus cyclo-
phosphamide. We initially opted for rituximab over cyclo-
phosphamide to reduce the risk of infertility. However, in
view of rapid clinical deterioration we commenced cyclo-
phosphamide. The RAVE and RITUXIVAS studies both
showed non-inferiority of rituximab compared to cyclo-
phosphamide in AAV [25, 26]. However, the results from
these trials cannot necessarily be extrapolated to our pa-
tient. In the RITUXIVAS trial all patients had glomerulo-
nephritis. The RAVE study was not restricted to patients
with renal involvement, but did not have any patients with
cranial nerve palsies in the rituximab treatment arm.
Nevertheless, case series suggest that rituximab can be
effective in cranial GPA [27, 28]. It should be highlighted
that rituximab has a relatively slow onset of action, and in
retrospect our initial “bridging” steroid therapy (one pulse
of 500 mg iv methyl prednisolone and 30 mg oral prednis-
olone) was insufficient. The patient improved markedly
after we commenced high-dose corticosteroids and cyclo-
phosphamide. For severe cases where rapid control of dis-
ease is necessary, this combination of cyclophosphamide
and rituximab may be preferable to either drug alone. In-
deed, in the RITUXIVAS trial i.v. cyclophosphamide
15 mg/kg was given alongside the rituximab doses in
weeks 1 and 3 [26].
Conclusions
Pituitary involvement is a rare complication of GPA. It
disproportionately affects female patients and tends to
occur early in the disease course. Diabetes insipidus is the
most commonly associated endocrinological abnormality.
Our case report highlights that localised GPA is not ne-
cessarily indolent and that methotrexate may be inad-
equate treatment for localised disease. The presence of
adverse features such as neurological involvement requires
prompt recognition and aggressive therapy. Organ- or
even life-threatening disease can occur in the absence of
pulmonary or renal involvement. In this case a good out-
come was achieved with high-dose steroid and dual treat-
ment with cyclophosphamide and rituximab with minimal
adverse events. In cases of severe neurological comprom-
ise due to GPA where a rapid therapeutic effect is re-
quired, such combination therapy may be a useful
strategy. Finally, such cases should be managed by a
multi-disciplinary team in a tertiary referral centre.
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Table 1 Previous reports of sellar involvement in GPA (Continued)
1st Author
& year
PMID No.
of cases
Age at GPA
diagnosis
Age at time
of sellar involvement
Sex Pituitary Imaging
(MRI unless stated)
Endocrinological
abnormalities
Non-CNS
features
ANCA
Homogenously
enhancing sellar
mass. Thickened
stalk.
Esposito
2017 [57]
28540625 3 37* 37 F Sellar mass
extending into the
suprasellar cistern
with peripheral
enhancement and
central cystic lesion.
Stalk deviation.
DI
Hypogonadism
GH deficiency
Constitutional,
ENT
PR3 +ve
36* 36 F Cystic pituitary mass DI
Anterior pituitary
function normal
Constitutional,
myalgia, ENT,
pulmonary
PR3 +ve
32* 32 F Sellar mass with
homogeneous.
Thickening of the
pituitary stalk
DI
Anterior pituitary
function normal
ENT PR3 +ve
Abbreviations: ACTH adrenocorticotropic hormone, cANCA cytoplasmic pattern ANCA staining, DI diabetes insipidus, GH growth hormone, IGF-1 insulin-like growth
factor 1, LH luteinising hormone, FSH follicular stimulating hormone, MPO myeloperoxidase, N/A data not available, PMID PubMed ID, PR3 proteinase-3, PS
posterior signal.
*indicates cases where pituitary involvement was diagnosed prior to or at the time of GPA diagnosis
For the purposes of the Table, a TSH within the reference range but inappropriately low for the T4 has been included in the category “↓ TSH”
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